Drug Profile
TVGV 1
Alternative Names: TVGV-1Latest Information Update: 28 Nov 2022
Price :
$50
*
At a glance
- Originator TheVax
- Class Cancer vaccines; Papillomavirus vaccines; Protein vaccines; Recombinant fusion proteins
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cervical cancer; Human papillomavirus infections
Most Recent Events
- 28 Nov 2022 No recent reports of development identified for preclinical development in Cervical-cancer(Combination therapy) in Taiwan
- 11 Oct 2021 No development reported - Phase-II for Human papillomavirus infections in USA (unspecified route) (NCT02576561)
- 11 Oct 2021 THEVAX Genetics Vaccine plans a clinical trial in Cervical cancer in Taiwan (THEVAX Genetics Vaccine website, October 2021)